Breast Cancer Therapeutics
Africa
Updated
Reviewed by Chandani Patel
Africa Vaccine Adjuvants Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$21.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $14.7 Mn | — | — |
| 2025 (base) | $16.2 Mn | +$1.5 Mn | — |
| 2026 (forecast) | $17.8 Mn | +$1.6 Mn | +9.9% |
| 2027 (forecast) | $19.5 Mn | +$1.8 Mn | +20.8% |
| 2028 (forecast) | $21.5 Mn | +$1.9 Mn | +32.7% |
| 2029 (forecast) | $23.6 Mn | +$2.1 Mn | +45.9% |
| 2030 (forecast) | $25.9 Mn | +$2.3 Mn | +60.3% |
| 2031 (forecast) | $28.5 Mn | +$2.6 Mn | +76.2% |
| 2032 (forecast) | $31.3 Mn | +$2.8 Mn | +93.6% |
| 2033 (forecast) | $34.4 Mn | +$3.1 Mn | +112.8% |
| 2034 (forecast) | $37.9 Mn | +$3.4 Mn | +133.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $16.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $37.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type and application (see all) |
| Key players | GSK PLC, Novavax, Croda International PLC, SEPPIC (Air Liquide), Dynavax Technologies (see all) |
| Regulator in Africa | AMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Vaccine adjuvants are ingredients added to vaccines to make the immune response stronger and longer-lasting.
Key segments of the vaccine Adjuvants market include type (Aluminum Salts, Emulsions and Saponin-Based) and application (Human Vaccines and Veterinary Vaccines).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the vaccine Adjuvants market.
Ready-to-use formulations, biosimilars and supply security programmes give the vaccine Adjuvants market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the vaccine Adjuvants market.
The vaccine Adjuvants market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The African Medicines Agency (AMA), set up by an African Union treaty in force since November 2021, aims to bring the work of national regulators together.[1] In some of the countries we cover here, medicines are approved by EDA (Egypt)[2], PPB (Kenya)[3], SAHPRA (South Africa)[4] and NAFDAC (Nigeria)[5]. How care is paid for in some of these countries: universal health insurance (Egypt)[6], the SHA (Kenya)[7], planned National Health Insurance (South Africa)[8] and out of pocket and the NHIA (Nigeria)[9].
[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
[2] Egyptian Drug Authority. Checked 14 Nov 2026.
[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[5] NAFDAC. Checked 19 Nov 2026.
[6] Universal Health Insurance Authority. Checked 14 Nov 2026.
[7] Social Health Authority. Checked 14 Nov 2026.
[8] National Department of Health. Checked 14 Nov 2026.
[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for vaccine Adjuvants. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
What doctors and scientists are doing in Vaccine Adjuvants right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Africa
Africa
Africa
Africa
Africa
Africa
Public Health · Africa
Medical Devices · Africa
Healthcare Services · Africa
Healthcare Services · Africa
Public Health · Africa
Healthcare Services · Africa